AlphAIAlphAI — Financial news for AI agents
proactiveinvestors.comSEP 152 min read$BHST

BioHarvest Sciences launches single-dose VINIA Daily Chews

BioHarvest Sciences Inc. (NASDAQ:BHST) launched single-dose VINIA Daily Chews, a new format for its red-grape cell composition. Each chew contains 400 mg of VINIA and 6 mg of piceid resveratrol, clinically shown to improve blood flow. The company aims to expand VINIA's market reach and demonstrate the potential of its Botanical Synthesis platform. The global gummy and chewable supplements market is projected to grow at 14.4% CAGR through 2030, according to Markets and Minds.

Original reporting
proactiveinvestors.com
Published Sep 15, 2026, 6:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 6:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BioHarvest Sciences launches single-dose VINIA Daily Chews — source image
Source · proactiveinvestors.com
Decision brief

The 30-second read

$BHSTBullishLow
01

Why it matters

The launch demonstrates commercial application of its platform, but financial impact remains uncertain.

02

Market read

A new consumer product rollout for a microcap biotech; modest trading relevance.

03

What to watch

Potential regulatory or supply-chain challenges for scaling the new format.

Relevance 5/10Novelty 6/10Timing: today

Background

BioHarvest Sciences focuses on botanical synthesis to create plant‑based compositions.

Company-level read

Ticker impact

$BHSTBullishMedium confidence
Context

BioHarvest Sciences announced the launch of VINIA Daily Chews, a new single-dose gummy product expanding its addressable market.

Expected impact

Modest upside if market perceives demand for the new format.

Evidence & confidence

Launch is a primary disclosure but limited to a niche supplement; scale is modest for a microcap.

Market effects

Sector

Highlights growth potential in the gummy and chewable supplements segment.

Regional

May increase interest in botanical supplement producers in North America.

Global

Limited to niche consumer health market.

Counterpoint

What could challenge this read

The market may view the launch as incremental and not material for a microcap.

Key entities

  • company
    BioHarvest Sciences Inc

    NASDAQ‑listed biotech firm developing botanical products.

  • executive
    Dr. Zaki Rakib

    CEO of BioHarvest Sciences.

Read at source← All news

Related articles

SEP 3
$AVGOMed

Dow climbs as stocks rebound on earnings, falling Treasury yields

Tiziana Life Sciences (TLSA) received a Buy rating and $7 price target from BTIG. Ocean Power Technologies (OPTT) is using Palantir Foundry to improve operations. Sintana Energy (SEI) reported TotalEnergies' acquisition of a 40% interest in Namibia’s PEL 83. American Resources (AREC) joined the Critical Minerals Institute. Thistle Resources (TRCG) launched a Phase 3 drill program. BioHarvest Sciences (BHST) plans to dual-list on the Tel Aviv Stock Exchange. Alvopetro Energy (ALV) reported August

proactiveinvestors.com3 min
AUG 13
$BHSTMed

BioHarvest Sciences Q2 Earnings Call Highlights

BioHarvest Sciences (NASDAQ:BHST) reported Q2 gross profit of $5.1M and a net loss of $3.7M ($0.17/share). Cash was $16.2M at June 30. 2026 revenue guidance was cut to $37M-$40M and EBITDA loss to $3M-$5M. Management tightened CDMO revenue to $4M-$5M and reduced VINIA outlook to $33M-$35M.

yahoo.com6 min
AUG 12
$BHSTMedAI 8/10

BioHarvest Sciences (BHST) Q2 2026 Earnings Call Transcript

BioHarvest Sciences (BHST) reported Q2 2026 revenue of $8.8 million, up 3.8% year over year, with gross profit of $5.1 million and a net loss of $3.7 million ($0.17/share). Cash rose to $16.2 million. The company revised 2026 revenue guidance to $37 million to $40 million and expects consolidated EBITDA losses of $3 million to $5 million, citing a shift toward CDMO growth and a rare fragrance supply agreement.

fool.com6 min
AUG 11
$BHSTMed

BIOHARVEST SCIENCES INC. (BHST): Financial results for Q2 2026

BIOHARVEST SCIENCES INC. (BHST) furnished an SEC Form 6-K — earnings release. BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update - Secured first ever CDMO Manufacturing Agreement supporting planned 20-ton commercial production program over two years for rare botanical fragrance, that BioHarvest expects to drive profitable

SEC EDGAR 6-K2 min
AUG 11
Med

BioHarvest Sciences Inc. Common Stock Q2 2026 Earnings Call Summary

BioHarvest Sciences reported a Q2 2026 earnings call focused on shifting capital from D2C to CDMO. It secured a CDMO manufacturing and supply deal for a rare fragrance, targeting $20m to $30m revenue in 2027-2028 and $180m over five years, with limited production in H1 2027. 2026 revenue guidance was cut to $37m-$40m, and it expects CDMO EBITDA loss of $1.5m-$2.5m and consolidated EBITDA breakeven in 2027.

yahoo.com6 min
AUG 11
$BHSTMedAI 8/10

BioHarvest posts higher Q2 revenue, secures manufacturing deal for premium fragrance compound

BioHarvest Sciences (BHST) reported Q2 revenue of $8.8M, up 3.8% y/y, with net loss of $3.7M ($0.17/sh) versus $4.1M ($0.24/sh) a year earlier. Operating expenses rose to $7.6M. Cash and equivalents plus deposits were $16.25M at June 30. It tightened CDMO guidance to $4M-$5M and cut VINIA guidance to $33M-$35M, and signed a UAE customer deal for 20 tons of a fragrance ingredient starting as early as H1 2027.

proactiveinvestors.com4 min